Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company Gilead Sciences
So what: Gilead said that most of the hepatitis C genotype 1 patients it treated with its GS-7977 drug relapsed after a course of treatment, triggering fresh concerns over the drug's efficacy in some patients. Naturally, the news bodes well for rival hep C treatment developers Vertex Pharmaceuticals
Now what: I'd look into this pullback as a possible buying opportunity. While Gilead was certainly dealt a setback, all companies in the hep C drug race will likely face the same challenge of treating the hepatitis C genotype 1 population with just one drug. Given the fact that it already has several drugs in its pipeline it can possibly combine with GS-7977, Gilead still seems like the smart bet to be the first to market.
Interested in more info on Gilead? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Gilead and Vertex. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Is Gilead Sciences, Inc. a Buy in 2018?
Focus on the future rather than the past for this big biotech.
2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.
5 Ways Gilead Sciences Plans to Return to Growth
Gilead's CEO reveals the biotech's game plan at the J.P. Morgan Healthcare Conference.